We are committed to creating microRNA (miRNA)-targeting therapies to improve the lives of patients in need. We believe that building strategic relationships is essential to achieving that mission.
At miRagen we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. This collaborative approach is making important contributions in our efforts to create miRNA-targeting therapies.
Together with miRagen’s in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development, these relationships uniquely position the company to evaluate and advance best-in-class technologies and high-potential drug candidates.
For more information on business development opportunities, please contact us at BusDev@miragenrx.com.
Servier is a privately-run French research-based pharmaceutical company with a significant presence in Europe and emerging markets. With particular expertise in the development of treatments for cardiovascular disease and a focus on advancing the most promising targets in specific disease areas, the company is well-aligned with miRagen’s approach to new therapeutics development. Servier supports the research and development of microRNA programs in the area of cardiovascular disease in a highly collaborative partnership.
miRagen and Servier entered into their strategic collaboration with the goal of advancing microRNA-based therapies for the treatment of cardiovascular disease. The collaboration is currently focused on developing MRG-110, targeting miR-92, for the treatment of cardiovascular disease.
Under the terms of the license and collaboration agreement, miRagen is eligible to receive certain development, regulatory, and commercial milestones as well as royalties on the sale of products under the strategic alliance. Servier funds a specified amount of the research and development of product candidates under the collaboration and is responsible for all costs of commercialization in its territory. miRagen retains all commercialization rights in the U.S. and Japan, and the option to co-sponsor any Phase III programs in the event that miRagen, alone or together with a partner, should seek marketing approvals for any of the targets in the U.S. and Japan.
Dr. Eric N. Olson’s laboratory at the University of Texas Southwestern Medical Center has identified multiple microRNAs that regulate critical processes in cardiovascular and muscle cell biology, uncovering profound and unexpected to roles of microRNAs in the development and progression of disease.
Through its expertise in mouse genetics, the Olson Lab provides miRagen with ongoing insights into the biology and therapeutic potential of specific microRNAs. We have been working closely with Dr. Olson’s group since our inception; this relationship has proven highly advantageous for the early identification of microRNAs important in disease processes and in assessing their potential for therapeutic targeting.
Roche owns and has proprietary rights to the Locked Nucleic Acid (LNA) drug platform utilizing its LNA chemistry. Under a license agreement with Roche, miRagen has been granted the exclusive rights to utilize the LNA drug platform in the research, development, and commercialization of a specified number of microRNA-targets.
t2cure is a German clinical-stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases. miRagen licensed rights to technology and intellectual property related to regarding microRNA 92 (miR-92), which is believed to be a key regulator of neoangiogenesis as part of ischemic disease. miRagen sublicensed certain rights to this technology to Servier and together with Servier under our collaboration we are developing a product candidate targeting miR-92, MRG-110, to treat patients who suffer from cardiovascular disorders.